Activity of anthracyclines in refractory ovarian cancer: Recent experience and review

Cancer Investigation

Volumn 15, Issue 4, 1997, Pages 329-334

  Garcia, Agustin ^a   Muggia, Franco M ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALTRETAMINE; ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROPYRIMIDINE; IFOSFAMIDE; PACLITAXEL;

ADULT; AGED; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION;

EID: 0030873627     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039736     Document Type: Review

References (51)

1. Thigpen JT, Bertelsen K, Eisenhauer EA, et al: Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol 4:S35-S40, 1993.
2. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989.
3. McGuire WP, Hosldns WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage 3 and stage 4 ovarian cancer. New Eng J Med 334:1-6, 1996.
4. Seidman AD, Reichman BS, Crown PA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995.
5. 4a. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997.
6. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 11:251-263, 1984.
7. Beck RE, Boyes DA: Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide. Can Med Assoc J 98(11):539-541, 1968.
8. Decker DG, Mussey E, Malkasian GD, et al: Cyclophosphamide in the treatment of ovarian cancer. Clin Obstet Gynecol 11(2):382-400, 1968.
9. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma, J Clin Oncol 5:756-767, 1987.
10. Barlow JJ, Piver MS, Chuang JT, et al: Adriamycin and bleomycin, alone and in combination in gynecological cancers. Cancer 32(4):735-743, 1973.
11. Young RC: Chemotherapy of ovarian cancer: Past and present. Semin Oncol 2(3):267-276, 1975.
12. de Palo GM, De Lena M, Di Re F, et al: Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 141(6):899-9902, 1975.
13. Lloyd RE, Jones SE, Salmon SE, et al: Combination chemotherapy with adriamycin (NSC 123127) and cyclophosphamide (NSC 26271) for solid tumors: A phase II trial. Cancer Treat Rep 60(1):77-83, 1976.
14. Omura GA, Morrow CP, Blessing JA, et al: A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adiamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51:783-789, 1983.
15. Young RC, Chabner BA, Hubbard SP, et al: Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 299:1261-1266, 1978.
16. Edmondson JH, Fleming TR, Decker DG, et al: Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep 63(2):241-247, 1979.
17. Wiltshaw E, Kroner T: Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55-60, 1976.
18. Williams CJ, Stevenson KE, Buchanan RB, et al: Advanced ovarian carcinoma: A pilot study of cis-dichlorodiammineplatinum (II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as single agent in previously treated patients. Cancer Treat Rep 63:1745-1753, 1979.
19. Sutton GP, Stehman FB, Einhorn LH, et al: Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223-229, 1989.
20. Kaye SB, Lewis CR, Paul J, et al: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992.
21. Ehrlich CE, Einhorn L, Williams SD, et al: Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinuni (II), adriamycin, and cyclophosphamide: A preliminary report. Cancer Treat Rep 63:281-288, 1979.
22. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57:1725-1730, 1986.
23. Neijt JP, ten Bokkel WW, van der Burg MEL, et al: Long term survival in ovarian cancer. Eur J Cancer 27:1367-1372, 1991.
24. Conte PF, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 4:965-971, 1986.
25. Hernadi Z, Juhashz B, Poka R, et al: Randomized trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4 epi-doxorubicin in the treatment of advanced ovarian cancer. Int J Gynecol Obstet 27:199-204, 1988.
26. Bertelsen K, Jakobson A, Andersen JE, et al: A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 28:161-169, 1987.
27. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A gynecologic oncology group study. J Clin Oncol 7:457-465, 1989.
28. Gruppo Interegionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987.
29. Hubbard SM, Barkes P, Young RC: Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. Cancer Treat Rep 62:1375-1377, 1978.
30. Bolts G, D'Incalci M, Gramellini F, et al: Adriamycin in ovarian cancer patients resistant to cyclophosphamide. Eur J Cancer 14:1401-1402, 1978.
31. Redman C, Lawton F, Stuart N, et al: Phase II study of combination 4′-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 23:51-53, 1989.
32. Gaducci A, Brunetti I, Muttini MP, et al: Epidoxorubicin and ionidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 30A:1432-1435, 1994.
33. Plosker GL, Faulds D: Epirubicin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs 45:788-856, 1993.
34. Vermorken JB, ten Bokkel Huinink WW, Kubieska A, et al: Antitumor activity of high dose epirubicin in patients with ovarian cancer (OC) failing platinum (P)-based regimens. Proc Am Assoc Cancer Res 31:188, 1990.
35. Vermorken JB, Kobierska A, Chevallier B, et al: Phase II study of high dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin (P). Proc Am Soc Clin Oncol 14:276, 1995, A772.
36. Metzner M, Logue J, Wilkinson PM, et al: Treatment of relapsed ovarian carcinoma with epirubicin, cis-platinum and 5-fluorouracil (ECF). Proc Am Soc Clin Oncol 14:278, 1995, A784.
37. Ahmed FY, King DM, Nicol B, et al: Preliminary results of infusional chemotherapy (cisplatin, epirubicin and 5-fluorouracil, ECF) for refractory and relapsed epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:280, 1995, A790.
38. du Bois A, Meerpohl HG, Madjar J, et al: Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer. J Cancer Res Clin Oncol 120:173-178, 1994.
39. Levi F, Benavides M, Chevelle C, et al: Chemotherapy of advanced ovarian cancer wilh 4′-0-tetrahydropyranyl doxorubicin and cisplalin: A randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 8:705-714, 1990.
40. Di Leo A, Nole F, Biganzoli L, et al: Mitoxantrone (DHAD) + ifosfamide (IFO) as salvage therapy in advanced platinum-refractory epithelial ovarian cancer (EOC). A phase II study by the I.T.M.O. Group. Ann Oncol 3(Suppl 5):A399, 1992.
41. Dufour P, Bergeral JP, Barats JC, et al: Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73:1865-1869, 1994.
42. Markman M, Homesley H, Norberts DA, et al: Phase I trial of intraperitoneal AD-32 in gynecologic malignancies. Gynecol Oncol 61:90-93, 1996.
43. Uziely B, Gabizon A, Jeffers S, et al: Liposomal doxorubicin (Doxil): Antitumor activity and unique toxicities during two complementary phase I studies. Proc Am Soc Clin Oncol 14:483, 1995, A1575.
44. Anonymous: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668-1674, 1991.
45. Fanning J, Bennet TZ, Hilgers RD: Meta-analysis of cisplatin, doxorubicin and Cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 80:954-960, 1992.
46. Levin L, Simon R, Hryniuk W: Importance of multi-agent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis. J Natl Cancer Inst 85:1732-1742, 1993.
47. Stewart LA, Guthrie D, Parmar MK, Williams CJ: Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials. Br Med J 303:884-893, 1991.
48. Conte PF: Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma. Bull Cancer 80:152-155, 1993.
49. A'Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13:726-732, 1995.
50. Holmes FA: Combination chemotherapy with taxol (Paclitaxel) in metastatic breast cancer. Ann Oncol 5(Suppl 6):523-527, 1994.
51. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.